skip to content

Amgen Inc.

AMGN-Q

258.60

1.50 (0.58%)

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm.

More at Wikipedia

Signal

Opinion

Expert

PAST TOP PICK

PAST TOP PICK

May 6, 2003

(Was a top pick on Apr 7. Up 7.4%) Still likes.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

May 6, 2003

(Was a top pick on Apr 7. Up 7.4%) Still likes.

Brian Acker, CA

☆ Unlock Ratings

Price

$60.970

Owned

Unknown

TOP PICK

TOP PICK

April 30, 2003

Three drugs are coming out which are blockbusters.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

April 30, 2003

Three drugs are coming out which are blockbusters.

Brian Acker, CA

☆ Unlock Ratings

Price

$61.300

Owned

Unknown

TOP PICK

TOP PICK

April 7, 2003

Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

April 7, 2003

Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way.

Brian Acker, CA

☆ Unlock Ratings

Price

$58.410

Owned

Unknown

BUY WEAKNESS

BUY WEAKNESS

January 13, 2003

Very successful biotech. Big growth. May be a little high.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

January 13, 2003

Very successful biotech. Big growth. May be a little high.

☆ Unlock Ratings

Price

$51.520

Owned

Unknown

BUY WEAKNESS

BUY WEAKNESS

August 13, 2002

18/20% growth for the next few years. Would prefer to buy in the $30's.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

August 13, 2002

18/20% growth for the next few years. Would prefer to buy in the $30's.

Andrew McCreath

☆ Unlock Ratings

Price

$45.641

Owned

Unknown

HOLD

HOLD

July 3, 2002

The biotech sector is down. A high quality company.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

July 3, 2002

The biotech sector is down. A high quality company.

☆ Unlock Ratings

Price

$35.830

Owned

Unknown

DON'T BUY

DON'T BUY

January 2, 2002

Doesn't like their run at Immunex.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

January 2, 2002

Doesn't like their run at Immunex.

☆ Unlock Ratings

Price

$56.400

Owned

Unknown

BUY WEAKNESS

BUY WEAKNESS

December 28, 2001

A little high now. Would buy at $50.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

December 28, 2001

A little high now. Would buy at $50.

Brian Acker, CA

☆ Unlock Ratings

Price

$59.060

Owned

Unknown

DON'T BUY

DON'T BUY

December 19, 2001

Too expensive.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

December 19, 2001

Too expensive.

Michelle Calpin

☆ Unlock Ratings

Price

$58.330

Owned

Unknown

BUY

BUY

July 31, 2001

A good buy and hold. Good products. Volatile.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

July 31, 2001

A good buy and hold. Good products. Volatile.

☆ Unlock Ratings

Price

$62.710

Owned

Unknown

BUY

BUY

July 6, 2001

Good broad spectrum. Volatile.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

July 6, 2001

Good broad spectrum. Volatile.

Glenn Paradis, BA, CFA

☆ Unlock Ratings

Price

$57.160

Owned

Unknown

PAST TOP PICK

PAST TOP PICK

June 6, 2001

(Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

June 6, 2001

(Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol.

John Sinkins, CFA

☆ Unlock Ratings

Price

$68.200

Owned

Unknown

TOP PICK

TOP PICK

February 22, 2001

Biotechs should grow substantially. A core company in the biotech sector. Has a pipeline. Profitable.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

February 22, 2001

Biotechs should grow substantially. A core company in the biotech sector. Has a pipeline. Profitable.

John Sinkins, CFA

☆ Unlock Ratings

Price

$70.063

Owned

Unknown

BUY WEAKNESS

BUY WEAKNESS

January 8, 2001

Likes. In late stage production

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

January 8, 2001

Likes. In late stage production

Noah Blackstein, B.A., CFA

☆ Unlock Ratings

Price

$58.688

Owned

Unknown

DON'T BUY

DON'T BUY

October 30, 2000

Facing risks on patents and drugs not that good.

Show full opinionHide full opinion

Amgen Inc. (AMGN-Q)

October 30, 2000

Facing risks on patents and drugs not that good.

Noah Blackstein, B.A., CFA

☆ Unlock Ratings

Price

$54.000

Owned

Unknown

Showing 91 to 105 of 105 entries

«
‹
3
4
5
6
7
›
»

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

PixFuture exclusive partner.

© Stockchase Inc.